公开(公告)号：US20180208658A1

公开(公告)日：2018-07-26

申请号：US15563912

申请日：2016-04-01

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Cheng LIU ,  Hong LIU ,  Yiyang XU ,  Jingyi XIANG ,  Li LONG

IPC: C07K16/28 ,  A61K39/395 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30

CPC classification number: C07K16/2809 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K2039/54 ,  C07K14/7051 ,  C07K14/70596 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/303 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an AFP peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

公开(公告)号：US10015953B2

公开(公告)日：2018-07-10

申请号：US15000751

申请日：2016-01-19

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Cagan Gurer ,  Ella Ioffe ,  Alexander Mujica ,  Gavin Thurston

IPC: A01K67/027 ,  C07K14/705 ,  C12N15/85 ,  G01N33/50 ,  C07K16/28

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0381 ,  C07K14/4703 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70596 ,  C07K16/2803 ,  C07K2319/00 ,  C07K2319/02 ,  C12N15/8509 ,  G01N33/5011 ,  G01N33/5014 ,  G01N33/5055 ,  G01N33/5088 ,  G01N2333/70596

Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

公开(公告)号：US20180185434A1

公开(公告)日：2018-07-05

申请号：US15740981

申请日：2016-06-29

Applicant: The Johns Hopkins University

Inventor： Ivan M. Borrello ,  Susan Lee ,  Kimberly A. Noonan ,  Drew M. Pardoll

IPC: A61K38/00 ,  A61K38/17 ,  C07K14/725 ,  C07K14/705 ,  C07K19/00 ,  C12N15/62 ,  A61K35/17 ,  A61K48/00 ,  A61P35/02 ,  C12N15/82

CPC classification number: A61K38/005 ,  A61K35/17 ,  A61K38/00 ,  A61K38/17 ,  A61K38/1709 ,  A61K48/005 ,  A61P35/02 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K19/00 ,  C12N15/62 ,  C12N15/8201

Abstract: In some aspects, the embodiments relate to compositions and methods related to chimeric transmembrane proteins. The chimeric transmembrane proteins may comprise the extracellular domain of an inhibitory receptor, and an intracellular signaling domain that can activate an immune response.

公开(公告)号：US10011635B2

公开(公告)日：2018-07-03

申请号：US15024928

申请日：2014-09-26

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  UNIVERSITY OF SOUTH FLORIDA ,  THE SCRIPPS RESEARCH INSTITUTE ,  MODULATION THERAPEUTICS

Inventor： Lori Hazlehurst ,  Christoph Rader ,  Xiuling Li ,  Mark McLaughlin

IPC: A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  C07K1/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K1/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/70596 ,  C07K2319/21 ,  C07K2319/30

Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).

公开(公告)号：US10005848B2

公开(公告)日：2018-06-26

申请号：US14725412

申请日：2015-05-29

Applicant: Genentech, Inc.

Inventor： Jackson G Egen ,  Jo-Anne Hongo ,  Steven Kauder ,  Robert A Lazarus ,  Lydia Santell ,  Yan Wu ,  Meredith Hazen ,  Wei-Ching Liang

IPC: C07K16/40 ,  C07K14/705 ,  C07K16/28 ,  C07K14/52 ,  C12Q1/68 ,  G01N33/74 ,  C12Q1/6883 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K14/52 ,  C07K14/70596 ,  C07K16/2863 ,  C07K2317/55 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/74 ,  G01N2333/71 ,  G01N2333/912 ,  G01N2800/065 ,  G01N2800/20 ,  G01N2800/52

Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.

公开(公告)号：US20180160663A1

公开(公告)日：2018-06-14

申请号：US15883477

申请日：2018-01-30

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Elena Burova ,  Yajun Tang ,  Ka-Man Venus Lai ,  Andrew J. Murphy

IPC: A01K67/027 ,  C07K14/705

CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/02 ,  A01K2267/03 ,  A01K2267/0331 ,  A61K49/0008 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/30

Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

公开(公告)号：US20180160661A1

公开(公告)日：2018-06-14

申请号：US15836089

申请日：2017-12-08

Applicant: ALECTOR LLC

Inventor： Arnon ROSENTHAL ,  Seung-Joo LEE

IPC: A01K67/027 ,  C12N15/85

CPC classification number: A01K67/0276 ,  A01K67/0275 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/07 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  C07K14/7056 ,  C07K14/70596 ,  C12N15/8509

Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

公开(公告)号：US09993546B2

公开(公告)日：2018-06-12

申请号：US15353847

申请日：2016-11-17

Applicant: The Johns Hopkins University

Inventor： Thomas August ,  Ernesto Marques, Jr.

IPC: A61K39/21 ,  C07H21/04 ,  C07K14/705 ,  C12N15/62 ,  C12N15/86 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/57 ,  C07H21/04 ,  C07K14/005 ,  C07K14/70596 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/06 ,  C07K2319/40 ,  C12N7/00 ,  C12N15/62 ,  C12N15/86 ,  C12N2740/16234 ,  C12N2750/14143

Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.

公开(公告)号：US20180147258A1

公开(公告)日：2018-05-31

申请号：US15513542

申请日：2015-09-25

Applicant: INNOVENT BIOLOGICS, INC.

Inventor： Yinjue Wang ,  Junfeng Li ,  Xiaole Huang

IPC: A61K38/17 ,  A61K47/26 ,  A61K47/18 ,  A61K47/02 ,  A61P27/02 ,  A61K9/08 ,  A61K9/00

CPC classification number: A61K38/179 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/711 ,  A61K38/1725 ,  A61K38/177 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61P27/02 ,  C07K14/70596 ,  C07K14/71 ,  C07K19/00 ,  C07K2319/00 ,  A61K2300/00

Abstract: Provided is a liquid formulation that enables the stable storage of recombinant fusion proteins, comprising a recombinant fusion protein, a buffer salt, a stabilizer, and a surfactant.

公开(公告)号：US20180105573A1

公开(公告)日：2018-04-19

申请号：US15568868

申请日：2016-04-26

Applicant: UCL BUSINESS PLC

Inventor： Martin Pulé ,  Shaun Cordoba

IPC: C07K14/705 ,  C07K16/28 ,  C07K19/00 ,  C12N9/02

CPC classification number: C07K14/70596 ,  C07K14/075 ,  C07K14/705 ,  C07K14/70503 ,  C07K16/2803 ,  C07K19/00 ,  C07K2319/02 ,  C07K2319/33 ,  C12N9/0071 ,  C12N2740/10043 ,  C12N2830/60

Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X—B in which A and B are nucleic acid sequences encoding a first and a second chimeric antigen receptor (CAR); and X is a nucleic acid sequence which encodes a cleavage site, wherein the first and second CAR recognise different antigens; the first and second CAR comprise or associate with activating endodomains; and (a) the first and/or second CAR comprises an intracellular retention signal; and/or (b) the signal peptide of the first or second CAR comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.